Антибиотикорезистентность как угроза национальной безопасности: фокус на мероприятия в амбулаторно-поликлиническом звене здравоохранения. Резолюция

1. WHO Global Strategy for Containment of Antimicrobial Resistance. World Health Organization, 2001. (Accessed 07, May, 2014, at http://www.who.int/
drugresistance/WHO_Global_Strategy_English.pdf?ua=1)
2. Устойчивость к противомикробным препаратам. Информационный бюллетень №194. WHO Media centre, 2013. (Accessed 07, May, 2014, at http://www.who.int/mediacentre/factsheets/fs194/ru/index.html)
3. Antimicrobial Resistance Global Report on surveillance. Webcast of Q&A Session on global report on surveillance, 2014. (Accessed 07, May, 2013, at http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1)
4. World Health Day 2011: policy briefs. WHO, 2011. (Accessed 07, May, 2014, at http://www.who.int/world-health-day/2011/policybriefs/en/)
5. http://www.tufts.edu/med/apua/consumers/personal_home_5_1451036133.pdf.
6. Roberts RR, Hota B, Ahmad I et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49: 1175–84.
7. US Department of Health and Human Services, Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. March 20, 2014. http: //www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf Accessed May 6, 2014.
8. IDSA Letter to President Obama on Antibiotic Resistance. February 19, 2014. (Accessed 07, May, 2014, at http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resistance/10x20/Letters/IDSA Letter to POTUS on Antibiotic Resistance.pdf)
9. Козлов Р.С., Сивая О.В., Кречикова О.И., Иванчик Н.В. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового исследования ПеГАС). Клин. микробиология и антимикроб. химиотерапия 2010; 12: 329-41.
10. Сивая О.В., Козлов Р.С., Кречикова О.И. и др. Антибиотикорезистентность Haemophilus influenzae в России: результаты многоцентрового исследования ПеГАС. Клин. микробиология и антимикроб. химиотерапия. 2014; 16: 57–69.
11. Сидоренко С.В., Грудинина С.А., Филимонова О.Ю. Резистентность к макролидам и линкозамидам среди Streptococcus pneumoniae и Streptococcus pyogenes в Российской̆ Федерации. Клин. фармакол. терапия. 2008; 17: 1–5.
12. Филимонова О.Ю., Грудинина С.А., Сидоренко С.В. и др. Антибиотикорезистентность штаммов Haemophilus influenzae, выделенных в Москве с 2002 по 2004 гг. Антибиотики и химиотерапия. 2004; 49: 14–20.
13. Грудинина С.А., Сидоренко С.В., Федорчук В.В. Динамика распространения антибиотикорезистентности среди Streptococcus pneumoniae в Москве в период с 1998 по 2003 гг. Антибиотики и химиотерапия. 2004; 49: 25–34.
14. Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34–42.
15. Metzler K, Drlica K, Blondeau JM. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 2013; 68: 631–5.
16. Costelloe C, Metcalfe C, Lovering A et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ (Clinical research ed) 2010; 340: c2096.
17. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288–97.
18. Ovetchkine P, Rieder MJ, and Canadian Paediatric Society Drug Therapy Hazardous Substances Committee. Azithromycin use in paediatrics: A practical overview. Paediatr Child Health 2013; 18: 311–6.
19. Gesink DC, Mulvad G, Montgomery-Andersen R et al. Mycoplasma genitalium presence, resistance and epidemiology in Greenland. Int J Circumpolar Health 2012; 71: 1–8.
20. Barkai G, Greenberg D, Givon-Lavi N et al. Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis 2005; 11: 829–37.
21. Greenberg D, Givon-Lavi N, Sharf AZ et al. The Association Between Antibiotic Use in the Community and Nasopharyngeal Carriage of Antibiotic-Resistant Streptococcus pneumoniae in Bedouin Children. Pediatr Infect Dis J 2008; 27: 776–82.
22. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11 (Suppl. 1): 35–43.
23. Савинова О.Ю., Сидоренко С.В., Буданов С.В., Грудинина С.А. Динамика распространения резистентности к бета-лактамным антибиотикам среди Streptococcus pneumoniae и ее клиническая значимость. Антибиотики и химиотерапия. 2010; 55: 12–20.
24. Mayanskiy N, Alyabieva N, Ponomarenko O et al. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis 2014; 20: 58–62.
25. Азовскова О.В., Иванчик Н.В., Дехнич А.В. и др., исследовательская группа «ПеГАС». Динамика антибиотикорезистентности респираторных штаммов Streptococcus pyogenes в России за период 1999–2009 гг. Клин. микробиология и антимикроб. химиотерапия. 2012; 14: 309–21.
26. Reinert RR, Filimonova OY, Al-Lahham A et al. Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob Agents Chemother 2008; 52: 2260–2.
27. Perepanova TS, Kozlov RS, Dekhnich AV et al. [Choice of antibacterial drugs in urinary infection]. Urologiia 2012: 4–8.
28. Палагин ИС, Сухорукова МВ, Дехнич АВ et al. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010–2011). Клин. микробиология и антимикроб. химиотерапия. 2012; 14: 280–302.
29. Козлов С.Н., Рафальский В.В., Галкин В.В. и др. Эффективность и безопасность цефиксима и ципрофлоксацина при остром цистите (многоцентровое рандомизированное исследование). Урология. 2011; 1: 13–6.
30. Рафальский В.В., Белокрысенко С.С., Малев И.В. и др. Чувствительность возбудителей инфекций мочевыводящих путей, выделенных в Российской Федерации к пероральному цефалоспорину III поколения цефиксиму. Лечащий врач. 2008: 27–9.
31. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103–20.
32. Резистентность возбудителей ИППП к антибактериальным препаратам. Информационный бюллетень 2010 год. М.: ДЭКС-ПРЕСС, 2010.
33. Bradley JS, Byington CL, Shah SS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of america. Clin Infect Dis 2011; 53: e25–76.
34. Hoffken G, Lorenz J, Kern W et al. [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. Pneumologie (Stuttgart, Germany) 2009; 63: e1–68.
35. Harris M, Clark J, Coote N et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 (Suppl. 2): ii1–23.
36. Lim WS, Baudouin SV, George RC et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1–iii55.
37. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. The European Committee on Antimicrobial Susceptibility Testing, 2014. (Accessed 08 May, 2014.)
38. Lieberthal AS, Carroll AE, Chonmaitree T et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131: e964–99.
39. Chow AW, Benninger MS, Brook I et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. Clin Infect Dis 2012; 54: e72–e112.
40. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect 2011; 17 (Suppl. 6): E1–59.
41. Le Saux N, Robinson J. Pneumonia in healthy Canadian children and youth: Practice points for management. Paediatr Child Health 2011; 16: 417–24.
42. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine, 2013. (Accessed 07, May, 2014, at http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624.pdf)
43. Drugmakers agree to new FDA rules restricting antibiotic use in livestock. Fierce Pharma, 2014. (Accessed 07, May, 2014, at http://www.fiercepharma.com/story/drugmakers-agree-new-fda-rules-restricting-antibiotic-use-livestoc...)
44. Dooley KE, Golub J, Goes FS et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607–12.
45. Chen TC, Lu PL, Lin CY et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011; 15: e211–6.
46. Shen GH, Tsao TC, Kao SJ et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 2012; 39: 201–5.
47. Asnis DS, Cherian S, Sun T et al. Pulmonary tuberculosis presenting as community-acquired pneumonia. Clin Infect Dis 2002; 35: 1574–5.
48. Kurbatova EV, Taylor A, Gammino VM et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinburgh, Scotland) 2012; 92: 397–403.
49. Punga VV, Jakubowiak WM, Danilova ID et al. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis 2009; 13: 1309–12.
50. Casali N, Nikolayevskyy V, Balabanova Y et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nature Genetics 2014; 46: 279–86.
51. World Health Organization. Global Tuberculosis Report 2012. Geneva: WHO; 2012.
52. Lee HJ, Park SK, Choi KY et al. Korean clinical practice guidelines: otitis media in children. J Korean Med Sci 2012; 27: 835–48.
53. Chiappini E, Regoli M, Bonsignori F et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther 2011; 33: 48–58.
54. Courter JD, Baker WL, Nowak KS et al. Increased Clinical Failures When Treating Acute Otitis Media with Macrolides: A Meta-Analysis (March) (FREE). Ann Pharmacother 2010.
55. Dagan R, Johnson CE, McLinn S et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatric Infect Dis J 2000; 19: 95–104.
56. Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Inf Dis 2002; 2: 593–604.
57. Dagan R, Leibovitz E, Fliss DM et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44: 43–50.
58. Зверков Ю.Б., Лелишенцев А.А., Липатова И.С. и соавт. Сравнительное фармакокинетическое исследование лекарственных форм амоксициллина. Клин. микробиология и антимикроб. химиотерапия. 2009; 11: 211–7.
59. 18th WHO Model List of Essential Medicines and the 4th Model List of Essential Medicines for Children. April 2013, Final Amendments – October 2013. WHO, 2013. (Accessed 08 May, 2014, at http://www.who.int/medicines/publications/essentialmedicines/en/index.html)
60. 18th WHO Model List of Essential Medicines. (Accessed 08 May, 2014, at http://www.who.int/medicines/publications/essentialmedicines/en/index.html)
61. Bar-Oz B, Bulkowstein M, Benyamini L et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf 2003; 26: 925–35.
62. Meropol SB, Localio AR, Metlay JP. Risks and benefits associated with antibiotic use for acute respiratory infections: a cohort study. Ann Family Med 2013; 11: 165–72.

проф. С.В.Яковлев, проф. С.В.Сидоренко, проф. В.В.Рафальский

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва